ADVA
11.5.2021 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 150-XG118Pro (CSH) , addressing urgent enterprise demand for high-bandwidth connectivity with robust security. The new member of the ADVA FSP 150 programmable demarcation and edge compute portfolio supports 10Gbit/s MEF 3.0 Carrier Ethernet and IP services, provides precise synchronization capabilities and now features hardware-based encryption. With its comprehensive MACsec security, the ADVA FSP 150-XG118Pro (CSH) enables business data to pass safely and seamlessly across untrusted public networks and empowers communication service providers (CSPs) to offer fully encrypted bandwidth services. What’s more, like ADVA’s FSP 3000 transport solution, the ADVA FSP 150-XG118Pro (CSH) is ready to run post-quantum cryptographic (PQC) algorithms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005059/en/
“Our FSP 150-XG118Pro (CSH) provides a simple and affordable route to high-capacity Carrier Ethernet connectivity with the highest levels of data protection. Unique in our industry, this compact and cost-efficient device combines demarcation, edge compute, synchronization and encryption,” said James Buchanan, GM, Edge Cloud, ADVA. “No other single solution offers all the features of our FSP 150-XG118Pro (CSH). Straight out of the box, it delivers data encryption compliant with the strictest standards in the industry, including FIPS 140-3. Our FSP 150-XG118Pro (CSH) has multi-layer demarcation capabilities as well as precise synchronization delivery. What’s more, its edge computing capabilities and open SDN control make it a key component for industrial IoT applications.”
The ADVA FSP 150-XG118Pro (CSH) combines 10Gbit/s MEF 3.0 Carrier Ethernet and IP service demarcation and aggregation with a rich set of programmability, synchronization and security features. For the first time, CSPs and businesses can deploy a compact and power-efficient solution with next-generation synchronization delivery, NFV-hosting capabilities and robust data protection. The FSP 150-XG118Pro (CSH) features precise clock technology based on Synchronous Ethernet and hardware processing of IEEE 1588 timestamps. Its fully open architecture supports ADVA’s Ensemble Connector and other virtual network function infrastructure. And, based on an enhanced version of MACsec able to encrypt across multiple domains and service provider networks, it provides end-to-end security across MEF Layer 2 cloud networks.
“Our FSP 150-XG118Pro (CSH) supports a smooth and simple transition from 1Gbit/s to 10Gbit/s services while meeting the very highest security requirements. Now there’s a simple and affordable way to achieve the safe and assured connectivity that businesses need for peace of mind and compliance with stringent regulations. The solutions also enables CSPs to roll out tailored encryption-as-a-service offerings,” commented Eli Angel, VP, product line management, ADVA. “Our FSP 150-XG118Pro (CSH) shares the same security framework as our optical products. Its cryptographic techniques, including dynamic key exchange and hardware tamper protection, ensure the safety of the most sensitive data. And, like our FSP 3000, it’s ready to support quantum-safe key exchange via a simple software upgrade.”
Watch this video for more information on the new FSP 150-XG118Pro (CSH): https://youtu.be/efdEFASaue8 .
Further details are also available in these slides: https://adva.li/fsp-150-xg118pro-csh-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005059/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom